E
Actavia Life Sciences, Inc. RASP
$0.004 -$0.0285-87.69%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 3/8/2023Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/8/2023 due to a major decline in the growth index, total return index and valuation index. EBIT declined 296.13% from -$31 to -$122.8, and earnings per share declined from -$0.0003 to -$0.0008.
D
Sell 2/13/2023Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 2/13/2023 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0051 to -$0.0003, and EBIT increased 75.76% from -$127.9 to -$31.
E
Sell 2/8/2023Downgrade
Actavia Life Sciences, Inc. (RASP) was downgraded to E+ from D- on 02/08/2023.
D
Sell 11/18/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/18/2022 due to an increase in the total return index.
E
Sell 8/23/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/23/2022 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.0018 to -$0.0051.
D
Sell 6/17/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 6/17/2022 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 0 to 0.01, and earnings per share increased from -$0.0046 to -$0.004.
E
Sell 6/13/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 6/13/2022 due to a noticeable decline in the growth index, volatility index and total return index.
D
Sell 5/5/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 5/5/2022 due to a substantial increase in the valuation index.
E
Sell 4/20/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0018 to -$0.0032.
D
Sell 11/23/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and volatility index.
E
Sell 11/8/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
D
Sell 10/6/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to D- from D on 10/6/2021 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell 8/20/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D from D- on 8/20/2021 due to a major increase in the growth index and total return index. Earnings per share increased from -$0.0039 to -$0.0018, operating cash flow increased 32.78% from -$121.1 to -$81.4, and EBIT increased 30.98% from -$93.6 to -$64.6.
D
Sell 3/26/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 3/26/2021 due to an increase in the total return index.
E
Sell 1/15/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 1/15/2021 due to a noticeable decline in the growth index. Operating cash flow declined 342.19% from $23.7 to -$57.4, and EBIT declined 43.74% from -$92.6 to -$133.1.
D
Sell 10/23/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 10/23/2020 due to an increase in the volatility index and total return index.
E
Sell 8/21/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/21/2020 due to a significant decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0028 to -$0.04.
D
Sell 7/1/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 7/1/2020 due to a substantial increase in the growth index and volatility index.
E
Sell 5/20/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 5/20/2020 due to a large decline in the growth index, efficiency index and volatility index.
D
Sell 4/14/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/14/2020 due to an increase in the volatility index.
E
Sell 3/26/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/26/2020 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 0.03 to 0.01, and debt to equity increased from 0.1 to 0.14.
D
Sell 4/4/2019Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/4/2019 due to an increase in the valuation index.
E
Sell 10/3/2018Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 10/3/2018 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.38 to 0.07.
D
Sell 7/5/2017Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E on 7/5/2017 due to a noticeable increase in the total return index and solvency index. The quick ratio increased from 1.18 to 2.71.
E
Sell 4/18/2017Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E from E+ on 4/18/2017 due to a noticeable decline in the volatility index and total return index.
E
Sell 4/3/2017Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to E+ from E on 4/3/2017 due to an increase in the growth index and valuation index.
E
Sell 3/16/2017None
Actavia Life Sciences, Inc. (RASP) was downgraded to E from U on 03/16/2017.
Weiss Ratings